Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression

Histone deacetylase (HDAC) inhibitors show clinical promise for the treatment of cancers, including hepatocellular carcinoma (HCC). In this study, we investigated the effect of HDAC inhibitor treatment on hepatitis C virus (HCV) replication in Huh7 human liver cells and in a mouse model of HCV infec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Virol Sin
Autors principals: Zhou, Yuan, Wang, Qian, Yang, Qi, Tang, Jielin, Xu, Chonghui, Gai, Dongwei, Chen, Xinwen, Chen, Jizheng
Format: Artigo
Idioma:Inglês
Publicat: Springer Singapore 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6235766/
https://ncbi.nlm.nih.gov/pubmed/30328580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12250-018-0057-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars